THE IMPORTANCE AND RELEVANCE OF OPTIMIZING MICROBIOTA COMPOSITION IN THE TREATMENT OF VARIOUS DISEASES

Authors

  • Zulfiya Baratovna Djuraeva Senior Lecturer of the Department of Microbiology, Virology, and Immunology.

Keywords:

Immune-mediated illnesses, gastrointestinal disorders, gut microbiota, microbial communities, microbiota regulation, safety concerns, treatment approaches, translational research

Abstract

The deliberate alteration of the microbial community's structure and function, known as microbiota modulation, is a new approach that has the potential to alleviate a plethora of health problems. The underlying concepts of microbiota regulation and its numerous applications to human health, healthcare administration, and pharmaceutical therapies are demonstrated in this review. There is a detailed description of many approaches, including nutritional treatments, fecal microbiota transplantation, antibiotic treatment, bacteriophages, microbiome engineering, and immune system regulation. Trillions of bacteria make up the gut microbiome, which has a significant impact on human health by influencing immunological responses, metabolism, and brain processes. Numerous inflammatory illnesses, metabolic problems, and neurological diseases are linked to disruptions in the composition of the gut microbiome. It is quite challenging to identify the underlying mechanisms and establish cause and effect, though. Preclinical models can uncover new therapeutic approaches and provide important insights into the involvement of the gut microbiota in illnesses. To evaluate the usefulness of preclinical models, such as animal and cell-based models, in clarifying the causative role of the gut microbiome in various diseases, the Human Microbiome Action Consortium launched a Delphi survey. The Delphi survey sought to solve the difficulty of choosing suitable preclinical models to properly explore host-microbiome interactions and examine disease etiology. To get opinions from a wide range of stakeholders, we used an organized method that included expert seminars, a literature review, and the Delphi questionnaire. In order to address the causal relationship between the gut microbiota and disease pathogenesis, experts were asked to assess the models' advantages, disadvantages, and applicability. The resulting suggestions and consensus statements offer important information for choosing preclinical models in upcoming research on disorders linked to the gut microbiota.

References

Augustynowicz G, Lasocka M, Szyller HP, Dziedziak M, Mytych A, Braksator J, Pytrus T. The Role of Gut Microbiota in the Development and Treatment of Obesity and Overweight: A Literature Review. Journal of Clinical Medicine. 2025; 14(14):4933. https://doi.org/10.3390/jcm14144933

El-Sayed, A.; Aleya, L.; Kamel, M. Microbiota’s Role in Health and Diseases. Environ. Sci. Pollut. Res. 2021, 28, 36967–36983.

Geng, J.; Ni, Q.; Sun, W.; Li, L.; Feng, X. The Links Between Gut Microbiota and Obesity and Obesity Related Diseases. Biomed. Pharmacother. 2022, 147, 112678.

Portincasa, P.; Bonfrate, L.; Khalil, M.; De Angelis, M.; Calabrese, F.M.; D’amato, M.; Wang, D.Q.H.; Di Ciaula, A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022, 10, 83.

Zheng, L.; Wen, X.L.; Duan, S.L.; Ji, Y.Y. Fecal Microbiota Transplantation in the Metabolic Diseases: Current Status and Perspectives. World J. Gastroenterol. 2022, 28, 2546.

Zheng, D.; Liwinski, T.; Elinav, E. Interaction between Microbiota and Immunity in Health and Disease. Cell Res. 2020, 30, 492–506.

Chao, J.; Coleman, R.A.; Keating, D.J.; Martin, A.M. Gut Microbiome Regulation of Gut Hormone Secretion. Endocrinology 2025, 166, bqaf004.

Hays, K.E.; Pfaffinger, J.M.; Ryznar, R. The Interplay Between Gut Microbiota, Short-Chain Fatty Acids, and Implications for Host Health and Disease. Gut Microbes 2024, 16, 2393270.

Kalkan, A.E.; BinMowyna, M.N.; Raposo, A.; Ahmad, M.F.; Ahmed, F.; Otayf, A.Y.; Carrascosa, C.; Saraiva, A.; Karav, S. Beyond the Gut: Unveiling Butyrate’s Global Health Impact Through Gut Health and Dysbiosis-Related Conditions: A Narrative Review. Nutrients 2025, 17, 1305.

Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. Signal Transduct Target Ther. 2022 Apr 23;7(1):135. doi: 10.1038/s41392-022-00974-4.

Berg G, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020;8:103. doi: 10.1186/s40168-020-00875-0.

Deo PN, Deshmukh R. Oral microbiome: unveiling the fundamentals. J. Oral. Maxillofac. Pathol. 2019;23:122–128. doi: 10.4103/jomfp.JOMFP_77_18.

Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 2021;19:55–71. doi: 10.1038/s41579-020-0433-9.

Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br. J. Nutr. 2020;123:1127–1137. doi: 10.1017/S0007114520000380.

Park JC, Im S-H. Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics. Exp. Mol. Med. 2020;52:1383–1396. doi: 10.1038/s12276-020-0473-2.

Gebrayel, P., Nicco, C., Al Khodor, S. et al. Microbiota medicine: towards clinical revolution. J Transl Med 20, 111 (2022). https://doi.org/10.1186/s12967-022-03296-9

Gu L, Ren F, Fang X, Yuan L, Liu G, Wang S. Exosomal MicroRNA-181a derived from mesenchymal stem cells improves gut microbiota composition, barrier function, and inflammatory status in an experimental colitis model. Front Med. 2021;10:898.

Han B, Lin CCJ, Hu G, Wang MC. ‘Inside Out’– a dialogue between mitochondria and bacteria. FEBS J. 2019;286(4):630–41. https://doi.org/10.1111/febs.14692.

Díaz-Garrido N, Badia J, Baldomà L. Microbiota-derived extracellular vesicles in interkingdom communication in the gut. J Extracell Vesicles. 2021;10(13): e12161. https://doi.org/10.1002/jev2.12161.

Riaz Rajoka MS, Mehwish HM, Xiong Y, Song X, Hussain N, Zhu Q, et al. Gut microbiota targeted nanomedicine for cancer therapy: Challenges and future considerations. Trends Food Sci Technol. 2021;107:240–51.

Ryan MJ, Schloter M, Berg G, Kostic T, Kinkel LL, Eversole K, et al. Development of microbiome biobanks – challenges and opportunities. Trends Microbiol. 2021;29(2):89–92. https://doi.org/10.1016/j.tim.2020.06.009.

Ugwu OP, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 2024 May 10;103(19):e38088. doi: 10.1097/MD.0000000000038088.

Wang Y, Li H. Gut microbiota modulation: a tool for the management of colorectal cancer. J Transl Med. 2022;20:178.

Angoorani P, Ejtahed HS, Hasani-Ranjbar S, et al. Gut microbiota modulation as a possible mediating mechanism for fasting-induced alleviation of metabolic complications: a systematic review. Nutr Metab (Lond). 2021;18:105.

Mutalub YB, Abdulwahab M, Mohammed A, et al. Gut microbiota modulation as a novel therapeutic strategy in cardiometabolic diseases. Foods. 2022;11:2575.

Araujo R, Borges-Canha M, Pimentel-Nunes P. Microbiota modulation in patients with metabolic syndrome. Nutrients. 2022;14:4490.

Metwaly, A., Kriaa, A., Hassani, Z. et al. A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research. Nat Rev Gastroenterol Hepatol 22, 343–356 (2025). https://doi.org/10.1038/s41575-025-01041-3

Lucchetti, M. et al. An organ-on-chip platform for simulating drug metabolism along the gut–liver axis. Adv. Healthc. Mater. 13, e2303943 (2024).

Shin, Y. C. et al. Three-dimensional regeneration of patient-derived intestinal organoid epithelium in a physiodynamic mucosal interface-on-a-chip. Micromachines 11, 663 (2020).

Zheng, J. et al. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat. Med. 30, 3555–3567 (2024).

Berg, G. et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome 8, 103 (2020).

Wensel, C. R., Pluznick, J. L., Salzberg, S. L. & Sears, C. L. Next-generation sequencing: insights to advance clinical investigations of the microbiome. J. Clin. Invest. 132, e154944 (2022).

Downloads

Published

2026-06-13